
Osteosarcoma Breakthrough GSK’s B7-H3 ADC GSK’227 Gains FDA Breakthrough Designation
GSK Receives FDA Breakthrough Therapy Designation for GSK5764227 in Osteosarcoma Treatment GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for…












